Goldman Sachs disclosed a $28.32 million holding in ImmunityBio. The position includes 3.23 million shares. This holding remained nearly unchanged from the previous reporting period. The stake is part of a broader $75 million investment across three biotech firms.
ImmunityBio is currently building commercial momentum for its cancer immunotherapy drug, Anktiva. The United Arab Emirates recently approved the treatment for specific bladder and lung cancers. The company expects an FDA decision regarding a U.S. label expansion by January 6, 2027.
Retail sentiment on Stocktwits remains bearish despite the institutional interest. Message volume for the stock is currently categorized as low.